Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3921383 | European Journal of Obstetrics & Gynecology and Reproductive Biology | 2007 | 4 Pages |
Abstract
Off-licence drugs are frequently given on grounds of cost, but cost constraints are not a defence to a claim of negligence. Sensible prescribing is key to managing the risks of using off-licence drugs. Whenever possible, licenced drugs supported by extensive clinical trial programs undertaken for regulatory approval should be used in preference to off-licence, unproven alternatives, particularly when both are equivalent in efficacy and no additional benefits are associated with use of the off-licence drug. Absence of evidence of harm is not the same as evidence of absence of harm.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Saj Shah, Herman van Geijn,